HARP - Harpoon crashes on plans to halt prostate cancer study

The clinical-stage immunotherapy company Harpoon Therapeutics (HARP -34.8%) have lost more than a third on Friday after announcing its plans to discontinue the clinical work on HPN424, an experimental therapy for prostate cancer. The decision followed “a careful and thorough analysis of our HPN424 data, including our clinical results to date,” Chief Executive Julie Eastland said with the company’s earnings release. “…based on those data we have made the decision to discontinue the HPN424 dose escalation study,” she added. Formerly the company’s lead candidate, HPN424, was undergoing a Phase 1/2a trial for metastatic castration-resistant prostate cancer. In December 2020, Harpoon (NASDAQ:HARP) reported that one patient out of seven showed confirmed partial response in the trial. The decision to halt the trial comes only a few months after Eastland took over as Harpoon’s (HARP) CEO in early November.

For further details see:

Harpoon crashes on plans to halt prostate cancer study